Format

Send to

Choose Destination
Transl Lung Cancer Res. 2017 Apr;6(2):186-195. doi: 10.21037/tlcr.2017.03.04.

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Author information

1
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
2
Division of Hematology-Oncology, Perelman Center for Advanced Medicine, Philadelphia, USA.

Abstract

Recent work with immunotherapy has shown promising results with treatment of several solid malignancies, and there are several reports of good systemic responses with the combination of immunotherapy and radiation therapy (RT), most notably in advanced melanoma. Given the rapid increase in the use of checkpoint blockade as well as anti-tumor vaccines, we review here the preclinical rationale and ongoing clinical work in combining immunotherapy with RT for small cell lung cancer (SCLC) and thymic tumors. While there are several reports of promising results with the combination of immunotherapy and conventional systemic treatment, we focus here on the ongoing clinical studies that combine immunotherapy with RT, and highlight the emerging data for this multimodality approach as well as key preclinical and clinical issues that remain to be addressed. With regards to SCLC, trials exploring to the combination of immunotherapy and RT are already ongoing, but clinical studies for this combination in thymoma are lacking.

KEYWORDS:

Immunotherapy; radiation; small cell lung cancer (SCLC); thymoma

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center